These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23554941)

  • 1. Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.
    Walsh MP; Duncan B; Larabee S; Krauss A; Davis JP; Cui Y; Kim SY; Guimond M; Bachovchin W; Fry TJ
    PLoS One; 2013; 8(3):e58860. PubMed ID: 23554941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
    Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
    Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
    Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
    Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
    Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
    J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function.
    Flentke GR; Munoz E; Huber BT; Plaut AG; Kettner CA; Bachovchin WW
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1556-9. PubMed ID: 1671716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.
    Duncan BB; Highfill SL; Qin H; Bouchkouj N; Larabee S; Zhao P; Woznica I; Liu Y; Li Y; Wu W; Lai JH; Jones B; Mackall CL; Bachovchin WW; Fry TJ
    J Immunother; 2013 Oct; 36(8):400-11. PubMed ID: 23994886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
    Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
    J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy.
    Blair TC; Bambina S; Alice AF; Kramer GF; Medler TR; Baird JR; Broz ML; Tormoen GW; Troesch V; Crittenden MR; Gough MJ
    J Immunol; 2020 Jun; 204(12):3416-3424. PubMed ID: 32341058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses.
    Thorne AH; Malo KN; Wong AJ; Nguyen TT; Cooch N; Reed C; Yan J; Broderick KE; Smith TRF; Masteller EL; Humeau L
    Front Immunol; 2020; 11():327. PubMed ID: 32161596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer.
    Teitz-Tennenbaum S; Li Q; Davis MA; Wilder-Romans K; Hoff J; Li M; Chang AE
    J Immunother; 2009; 32(6):602-12. PubMed ID: 19483649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.